Autori: Kivitz Alan J
Naslov | Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate (Article) |
Autori | Robinson Michael F Damjanov Nemanja S Stamenkovic Bojana N Radunovic Goran L Kivitz Alan J Cox Lori Manukyan Zorayr Banfield Christopher Saunders Michael Chandra Deepa Vincent Michael S Mancuso Jessica Peeva Elena Beebe Jean S |
Info | ARTHRITIS & RHEUMATOLOGY, (2020), vol. 72 br. 10, str. 1621-1631 |
Projekat | Pfizer, Inc.Pfizer |
Ispravka | Web of Science Članak Elečas Rang časopisa Citati: Web of Science Scopus |
|
Naslov | Efficacy and Safety of PF-06651600 (Ritlecitinib), a Novel JAK3/TEC Inhibitor, in Patients With Moderate-to-Severe Rheumatoid Arthritis and an Inadequate Response to Methotrexate (Article) |
Autori | Robinson Michael F Damjanov Nemanja S Stamenkovic Bojana N Radunovic Goran L Kivitz Alan J Cox Lori Manukyan Zorayr Banfield Christopher Saunders Michael Chandra Deepa Vincent Michael S Mancuso Jessica Peeva Elena Beebe Jean S |
Info | ARTHRITIS & RHEUMATOLOGY, (2020), vol. 72 br. 10, str. 1621-1631 |
Projekat | Pfizer, Inc.Pfizer |
Ispravka | Web of Science Članak Elečas Rang časopisa Citati: Web of Science Scopus |
|
Naslov | A Randomized, Double-Blind, Placebo-Controlled, Twelve-Week, Dose-Ranging Study of Decernotinib, an Oral Selective JAK-3 Inhibitor, as Monotherapy in Patients With Active Rheumatoid Arthritis (Article) |
Autori | Fleischmann Roy M Damjanov Nemanja S Kivitz Alan J Legedza Anna Hoock Thomas Kinnman Nils |
Info | ARTHRITIS & RHEUMATOLOGY, (2015), vol. 67 br. 2, str. 334-343 |
Projekat | Vertex Pharmaceuticals Incorporated |
Ispravka | Web of Science Članak Elečas Rang časopisa Citati: Web of Science Scopus |
|